PALO ALTO — It’s going to be a very busy year for lawyers who take companies public.
For months, the buzz on initial public offerings has been all about the renaissance in the life sciences. But after the biggest flurry of activity in biotechs in a decade—14 IPOs priced between Jan. 29 and Feb. 11—IPO lawyers now see a huge wave of straight-tech IPOs lining up.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
